Company Number: 13775713

Analysis Date: 2025-07-20 14:20 UTC

1. Risk Rating: LOW
   The company demonstrates a solid net asset position and no current liabilities, indicating strong solvency and liquidity. It has filed accounts and confirmation statements on time, which supports compliance and operational stability.

2. Key Concerns:

• No employees reported in the last two years, which may indicate reliance on directors or external contractors and could affect scalability and operational capacity.
• Minimal share capital (£55) relative to net assets, suggesting capital structure is heavily based on reserves or shareholder loans, which merits further review for financial resilience.
• Lack of audit due to micro-entity status reduces external verification of financial data, requiring reliance on internal controls and governance quality.

3. Positive Indicators:

• Consistent increase in current assets from £354,548 in 2023 to £560,741 in 2024 with zero current liabilities, showing strong liquidity.
• Net assets increased from £399,548 in 2023 to £605,741 in 2024, indicating growth and retained earnings or capital injections.
• Timely filing of accounts and confirmation statements with no overdue filings, reflecting good regulatory compliance.
• Majority ownership and control by a single PSC (Adam David George) may facilitate decisive management and strategic alignment.

4. Due Diligence Notes:

• Investigate the nature of current assets (e.g., cash, receivables, investments) to confirm liquidity quality and assess any encumbrances or restrictions.
• Review the composition of shareholders’ funds and any related party transactions or shareholder loans to understand financial structure and risk exposure.
• Clarify operational model given zero reported employees—determine if activities are outsourced, reliant on contracted personnel, or if the company is in an early development stage.
• Assess directors’ experience and governance practices, especially given the company’s focus on biotechnology research and pharmaceutical manufacturing, which are capital-intensive and regulated sectors.
• Confirm that exemption from audit does not mask any financial reporting risks by reviewing internal controls or seeking additional assurances.